FDA Discusses Biosimilars

The government says regulatory requirements for generic biological therapies will have to be tailored to the treatment in question.

By | August 8, 2011

Senior officials at the US Food and Drug Administration laid out their guiding philosophy on regulating the production of generic versions of biological drugs such as antibodies, insulin or other proteins last Wednesday (August 3) in the New England Journal of Medicine.

Biologics generally have a more complicated production process than small molecule drugs, impeding the ability of generic manufacturers to prove they are producing an identical drug. Drug companies, therefore, have been eagerly awaiting guidance from the FDA as to what constitutes a sufficient level of "biosimilarity" to allow a generic version of a drug to be approved.

In the article, Janet Woodcock, the director of the FDA’s Center for Drug Evaluation and Research (CDER), and others said that "given the complex nature of biologics, it's unlikely that a 'one size fits all' systematic assessment of biosimilarity can be developed."   While the article further stated that unnecessary "and therefore unethical" clinical and preclinical testing of biosimilars should be avoided, it also suggested that more data will be necessary to determine a generic’s similarity to the original than what is required for small molecule generics, according to Reuters.

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Comments

Avatar of: prasanta

Anonymous

August 8, 2011

When the world is trying to rationalize on the availability of life-saving biologics at affordable prices , regulatory  complications are expected to be ironed out .

Avatar of:

Posts: 0

August 8, 2011

When the world is trying to rationalize on the availability of life-saving biologics at affordable prices , regulatory  complications are expected to be ironed out .

Avatar of:

Posts: 0

August 8, 2011

When the world is trying to rationalize on the availability of life-saving biologics at affordable prices , regulatory  complications are expected to be ironed out .

Popular Now

  1. How Plants Evolved Different Ways to Make Caffeine
  2. Thomson Reuters Predicts Nobelists
    The Nutshell Thomson Reuters Predicts Nobelists

    According to citation statistics, researchers behind programmed cell death pathways and CRISPR/Cas9 are among those in line for Nobel Prizes this year.

  3. Monsanto Buys Rights to CRISPR
    The Nutshell Monsanto Buys Rights to CRISPR

    The US agribusiness secures a global, nonexclusive licensing agreement from the Broad Institute to use the gene-editing technology for agricultural applications.

  4. Reviewing Results-Free Manuscripts
    The Nutshell Reviewing Results-Free Manuscripts

    An open-access journal is trialing a peer-review process in which reviewers do not have access to the results or discussion sections of submitted papers.

RayBiotech